Keywords: Merck & Co, Financial results, Fourth-quarter and full-year 2012

Merck & Co sales and earnings fall, hit by patent expiries, but beat expectations

Article | 04 February 2013

Print This

Shares of US pharma giant Merck & Co (NYSE: MRK) tracked 2.9% lower to $41.98 Friday morning, when the company reported financial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in